Dyne Therapeutics (NASDAQ:DYN) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Dyne Therapeutics (NASDAQ:DYN) posted its earnings results on Monday. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.01, reports.

Dyne Therapeutics Price Performance

NASDAQ:DYN opened at $15.62 on Monday. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.47 and a quick ratio of 13.47. Dyne Therapeutics has a one year low of $6.36 and a one year high of $25.00. The company has a fifty day moving average price of $17.57 and a 200 day moving average price of $17.01. The stock has a market cap of $2.23 billion, a P/E ratio of -4.27 and a beta of 1.34.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd bought a new position in Dyne Therapeutics during the fourth quarter valued at about $84,000. Steward Partners Investment Advisory LLC grew its holdings in shares of Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after purchasing an additional 2,465 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Dyne Therapeutics by 275.1% during the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after purchasing an additional 7,697 shares during the period. Prudential Financial Inc. acquired a new position in shares of Dyne Therapeutics in the second quarter valued at $111,000. Finally, Creative Planning raised its stake in shares of Dyne Therapeutics by 23.8% in the second quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after purchasing an additional 2,797 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on DYN. Tudor Pickering set a $23.00 target price on Dyne Therapeutics in a report on Tuesday, December 9th. HC Wainwright raised their price objective on Dyne Therapeutics from $46.00 to $60.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Robert W. Baird set a $30.00 target price on Dyne Therapeutics in a research report on Monday, December 8th. Chardan Capital reiterated a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a report on Tuesday, December 9th. Finally, Oppenheimer upgraded shares of Dyne Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $11.00 to $40.00 in a research note on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $37.81.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.